ALK and non-small cell lung carcinoma: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) on chromosome 2p was first identified as oncogenic driver mutations in 2007 in Japanese NSCLC patients [7].